Abstract
Purpose: This study was designed to assess the 3-year experience with superselective intraarterial chemotherapy prior to definitive treatment for stages III and IV squamous cell carcinomas of the mouth.
Methods: Twenty-two patients prospectively received superselective intraarterial chemotherapy using relatively low-dose cisplatin via a transfemoral approach. The locations of the tumors were the tongue (n=12), gingiva (n=5), buccal mucosa (n=2), hard palate (n=1), floor of the mouth (n=1), and lip (n=1). After intraarterial chemotherapy, 21 patients underwent surgery (n=14), radiation therapy (n=6), or both (n=1). The survival rate of 25 patients who underwent surgery with/without radiationtherapy until 1992 at Kumamoto University Hospital was also evaluated as a historical control. The survival curve was calculated with the Kaplan-Meier method, and the statistical difference between survival curves was determined with the generalized Wilcoxon test.
Results: The overall response rate was 95% [complete response (tumor completely resolved), 24%; partial response (tumor reduction ≥50%), 71%]. Fifty-two intraarterial infusions were performed without any catheter-related complications. Mild and transient local toxicity such as edema or mucositis of the infused area was relatively common. One patient died of renal failure from cisplatin. After a median follow-up of 20 months (range 2–41 months), the estimated 3-year survival rate for patients who underwent intraarterial chemotherapy plus surgery was 91%. The survival of the patients who underwent intraarterial chemotherapy plus surgery tended to be longer than that of the historical control.
Conclusions: Early tumor reduction without delay of subsequent treatments can be obtained by intraarterial chemotherapy while minimizing complications and possibly improving survival. Further investigations of long-term survival with larger series need to be performed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Toohill RJ, Anderson T, Byhardt RW, Cox JD, Duncavage JA, Grossman TW, Haas JS, Hartz AJ, Libnoch JA, Malin TC, Ritch PS, Wilson FW (1987) Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. Arch Otolaryngol Head Neck Surg 113:758–761
Brunin F, Rodriguez J, Jaulerry C, Jouve M, Pontvert D, Point D, Mosseri V, Pouillart P, Asselain B, Brougere J, Bataini JP (1989) Induction chemotherapy in advanced head and neck cancer: Preliminary results of a randomized study. Acta Oncol 28:61–65
Veterans Affairs Laryngeal Cancer Study Group V (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690
Baker SR, Wheeler R (1984) Intraarterial chemotherapy for head and neck cancer, part 2: Clinical experience. Head Neck Surg 6:751–760
Baker SR, Forastiere AA, Wheeler RH, Medvec BR (1987) Intraarterial chemotherapy for head and neck cancer: An update of the totally implantable infusion pump. Arch Otolaryngol Head Neck Surg 113:1183–1190
Cheung DK, Regan J, Savin M, Gibberman VAL, Woessner W (1988) A pilot study of intraarterial chemotherapy with cisplatin in locally advanced head and neck cancers. Cancer 61:903–908
Lee YY, Dimery IW, Van Tassel V, De Pena C, Blacklock JB, Goepfert H (1989) Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Head Neck Surg 115:503–511
Shimizu T, Sakakura Y, Hattori T, Yamaguchi N, Kubo M, Sakakura K (1990) Superselective intraarterial chemotherapy in combination with irradiation: Preliminary report. Am J Otolaryngol 11:131–136
Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB (1992) Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 14:364–371
Korogi Y, Hirai T, Nishimura R, Hamatake S, Sakamoto Y, Murakami R, Baba Y, Arakawa A, Takahashi M, Uji Y, Taen A (1995) Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: Preliminary clinical experience. AJR 165:1269–1272
Robbins KT, Fontanesi J, Wong FS, Vicario D, Seagren S, Kumar P, Weisman R, Pellitteri P, Thomas JR, Flick P, Palmer R, Weir A, Kerber C, Murry T, Ferguson R, Los G, Orloff L, Howell SB (1996) A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Arch Otolaryngol Head Neck Surg 122:853–857
Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J (1987) Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: Preliminary report by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 13:41–47
Lusinchi A, Lartigau E, Luboinski B, Eschwege F (1994) Accelerated radiation therapy in the management of very advanced and inoperable head and neck cancers. Int J Radiat Oncol Biol Phys 29:149–152
Antognoni P, Bignardi M, Cazzaniga F, Poli AM, Richetti A, Bossi A, Rampello G, Barbera F, Soatti C, Bardelli D, Giordano M, Danova M (1996) Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kinetics: A phase II multicenter study. Int J Radiat Oncol Biol Phys 36:1137–1145
Stell PM (1992) Adjuvant chemotherapy in head and neck cancer. Sem Radiat Oncol 2:195–205
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hirai, T., Korogi, Y., Hamatake, S. et al. Stages III and IV squamous cell carcinoma of the mouth: Three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment. Cardiovasc Intervent Radiol 22, 201–205 (1999). https://doi.org/10.1007/s002709900366
Issue Date:
DOI: https://doi.org/10.1007/s002709900366